SCHEMBL5650003

SCHEMBL5650003

CCC(N)(Cc1ccccc1)C1CCNCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.45
HRH1 P35367 4/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
CYP2D6 P10635 1/20 0.42
SCN1A P35498 1/20 0.42
KMT2A Q03164 1/20 0.42
SCN2A Q99250 1/20 0.42
SCN3A Q9NY46 1/20 0.42
SLC6A2 P23975 5/20 0.42
TAAR1 Q96RJ0 1/20 0.42
GABRA1 P14867 2/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
SLC6A4 P31645 4/20 0.38
SLC18A3 Q16572 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
SLC6A3 Q01959 3/20 0.36
HTR1A P08908 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651523 0.82 SLC6A2 (0.50) GBA1HRH1MEN1LMNACYP2D6
SCHEMBL247607 0.77 ARG1 (0.35) HRH1MEN1LMNACYP2D6SCN1A
SCHEMBL9978781 0.77 GBA1 (0.50) GBA1HRH1MEN1LMNACYP2D6
Hydrochloric Acid SCHEMBL6150114 0.75 ARG1 (0.34) HRH1MEN1LMNACYP2D6SCN1A
SCHEMBL11861949 0.74 HRH1 (0.53) GBA1HRH1MEN1LMNACYP2D6
SCHEMBL28021430 0.73 HRH1 (0.56) GBA1HRH1MEN1LMNACYP2D6
SCHEMBL5649395 0.73 GBA1 (0.46) GBA1HRH1MEN1LMNACYP2D6
Hydrochloric Acid SCHEMBL11843236 0.73 HRH1 (0.51) GBA1HRH1MEN1LMNACYP2D6
SCHEMBL27714822 0.73 HRH1 (0.44) GBA1HRH1MEN1LMNACYP2D6
SCHEMBL4711345 0.73 SLC6A3 (0.39) HRH1MEN1LMNACYP2D6SCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL GBA1 451/4885HRH1 1408/4885MEN1 2277/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL GBA1 474/4885HRH1 1370/4885MEN1 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.